About
   About the YMJ
   Editorial Board
  View Full-text
   Current Issue
   Archive
   YMJ on
   YMJ on
   YMJ Search
  For Contributors
   Information for Contributors
   e-Submission
   
   
     
     
     
     
     
     
 
 
 
Table of Contents > Abs + Ref
   |    |  Full-text      |  
Yonsei Med J. 2009 Jun;50(3):331-334.
Published online 2009 June 23.  doi: 10.3349/ymj.2009.50.3.331.
© Copyright: Yonsei University College of Medicine 2009
Genetic and Epigenetic Marker-Based DNA Test of Stool Is a Promising Approach for Colorectal Cancer Screening
Sung Whan An,1,2 Nam Kyu Kim,3 and Hyun Cheol Chung1,4
1Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea.
2Genomictree, Inc., Daejeon, Korea.
3Department of General Surgery, Yonsei University College of Medicine, Seoul, Korea.
4Yonsei Cancer Center, Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author: Dr. Sung Whan An, Genomictree, Inc., 829 Tamnip-dong, Yuseong-gu, Daejeon 305-510, Korea. Tel: 82-42-861-4550, Fax: 82-42-861-4552, Email: sungwhan@genomictree.com
Received May 02, 2009.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abstract

Colorectal cancer (CRC) is one of the most common malignancies and leading cause of cancer-related deaths in the world.1 However, it may be treated effectively by surgical removal of the cancerous tissue if detected at early stages. Conventional tools for screening CRC are either invasive or inaccurate. Therefore, there is an urgent need to develop a reliable screening tools for CRC to significantly reduce its morbidity. In this regard, a novel DNA markers-based detection in stool is emerging as a promising approach.

Keywords: Colorectal cancer screening, stool DNA, genetic and epigenetic alterations.
References
1. Dong SM,Traverso G,Johnson C,Geng L,Favis R,Boynton K,et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858–865.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533–543.
3. Grady WM,Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101–128.
4. Eastwood M. Diet and intestinal disease. Compr Ther 1977;3:19–23.
5. Boynton KA,Summerhayes IC,Ahlquist DA,Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003;49:1058–1065.
6. Mak T,Lalloo F,Evans DG,Hill J. Molecular stool screening for colorectal cancer. Br J Surg 2004;91:790–800.
7. Ahlquist DA,Skoletsky JE,Boynton KA,Harrington JJ,Mahoney DW,Piercall WE,et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219–1227.
8. Imperiale TF,Ransohoff DF,Itzkowitz SH,Turnbull BA,Ross ME. Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704–2714.
9. Itzkowitz SH,Jandorf L,Brand R,Rabeneck L,Schroy PC 3rd,Sontag S,et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007;5:111–117.
10. Diehl F,Schmidt K,Durkee KH,Moore KJ,Goodman SN,Shuber AP,et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008;135:489–498.
11. Zou H,Taylor WR,Harrington JJ,Hussain FT,Cao X,Loprinzi CL,et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 2009;136:459–470.
12. Song K,Fendrick AM,Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004;126:1270–1279.
13. Baylin SB. Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 2002;12:331–337.
14. Jones PA,Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163–167.
15. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253–266.
16. Issa JP. The epigenetics of colorectal cancer. Ann N Y Acad Sci 2000;910:140–153.
discussion 153-5
17. Muller HM,Oberwalder M,Fiegl H,Morandell M,Goebel G,Zitt M,et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening?. Lancet 2004;363:1283–1285.
18. Wang DR,Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 2008;14:524–531.
19. Huang Z,Li L,Wang J. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 2007;52:2287–2291.
20. Oberwalder M,Wonter C,Wöntner C,Fiegl H,Goebel G,Zitt M,et al. SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis 2008;23:15–19.
21. Zhang W,Bauer M,Croner RS,Pelz JO,Lodygin D,Hermeking H,et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum 2007;50:1618–1626.
discussion 1626-7
22. Chen WD,Han ZJ,Skoletsky J,Olson J,Sah J,Myeroff L,et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005;97:1124–1132.
23. Olson J,Whitney DH,Durkee K,Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol 2005;14:183–191.
24. Whitney D,Skoletsky J,Moore K,Boynton K,Kann L,Brand R,et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn 2004;6:386–395.
25. Anti M,Armuzzi A,Morini S,Iascone E,Pignataro G,Coco C,et al. Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut 2001;48:238–246.
26. Glöckner SC,Dhir M,Yi JM,McGarvey KE,Van Neste L,Louwagie J,et al. Methylation of TFPI2 in Stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009;69:4691–4699.
27. Wong CM,Ng YL,Lee JM,Wong CC,Cheung OF,Chan CY,et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007;45:1129–1138.
28. Sato N,Parker AR,Fukushima N,Miyagi Y,Iacobuzio-Donahue CA,Eshleman JR,et al. Epigenetic inactivation of TPFI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005;24:850–858.
29. Nobeyama Y,Okochi-Takada E,Furuta J,Miyagi Y,Kikuchi K,Yamamoto A,et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 2007;121:301–307.
30. Rollin J,Iochmann S,Bléchet C,Hubé F,Régina S,Guyétant S,et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005;92:775–783.
31. Shames DS,Girard L,Gao B,Sato M,Lewis CM,Shivapurkar N,et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006;3:e486.
32. Sova P,Feng Q,Geiss G,Wood T,Strauss R,Rudolf V,et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006;15:114–123.